Floseal Matrix: New Generation Topical Hemostatic Sealant

Journal of Cardiac Surgery

Volumn 18, Issue 6, 2003, Pages 486-493

  Oz, Mehmet C ^a   Rondinone, Joseph F ^b   Shargill, Narinder S ^b  

^a Columbia University ^*  (United States)

^b Fusion Medical Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIFOAM; BIOGLUE; CELLULOSE; COLLAGEN; COSTASIS; FIBRIN GLUE; FLOSEAL; GELATIN; GELFOAM; HELISTAT; HEMASEEL; HEMOSTATIC; HEMOSTATIC AGENT; INSTAT; MICROCRYSTALLINE COLLAGEN; OXIDIZED CELLULOSE; OXIDIZED REGENERATED CELLULOSE; PARECOXIB; SEALANT; SURGIFOAM; THROMBIN JMI; UNCLASSIFIED DRUG;

BLEEDING; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFECT; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MIXTURE; DRUG SAFETY; FREEZE DRYING; HEMOSTASIS; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

GELATIN SPONGE, ABSORBABLE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS;

EID: 0344825764     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0886-0440.2003.00302.x     Document Type: Conference Paper

References (23)

1. Despotis GJ, Filos KS, Zoys TN, et al: Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg 1996;82:13-21.
2. Collins JA: Recent developments in the area of massive transfusion. World J Surg 1987;11:75-81.
3. Kalter RD, Saul CM, Wetstein L, et al: Cardiopulmonary bypass: Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979;77:427-435.
4. Mammen EF, Koets MH, Washington BC, et al: Hemostasis changes during cardiopulmonary bypass. Semin Thromb Hemost 1985;11:281-295.
5. Rohrer MJ, Natale AM: Effect of hypothermia on the coagulation cascade. Crit Care Med 1992;20:1402-1405.
6. Valeri CR, Feingold H, Cassidy G, et al: Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987;205:175-181.
7. McKenna R, Bachmann F, Whittaker B, et al: The hemostatic mechanism after open-heart surgery: Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-308.
8. Bick RL: Alterations of hemostasis associated with cardiopulmonary bypass: Pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost 1976;3:59-82.
9. Holloway DS, Summaria L, Sandesara J, et al: Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988;59:62-67.
10. Friedenberg WR, Myers WO, Plotka ED, et al: Platelet dysfunction associated with cardiopulmonary bypass. Ann Thorac Surg 1978;25:298-305.
11. Oz M, Cosgrove III DM, Badduke BR, et al., for the Fusion Matrix Study Group: Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg 2000;69:1376-1382.
12. Renkens Jr. KL, Payner T, Leipzig TJ, et al: Multicenter, prospective, randomized trial evaluating a new hemostatic agent in spinal surgery. SPINE 2001;26(15 Suppl):1645-1650.
13. Reuthebach O, Lachat ML, Vogt P, et al: FloSeal®: A new hemostyptic agent in peripheral vascular surgery. VASA 2000;29:204-206.
14. Hood DB, Weaver FA, Messina LM, et al: Efficacy of topical hemostat FloSeal™ Matrix in vascular surgery. Cardiovasc Surg 1999;7(1 Suppl):149.
15. Izzo F, Delrio P, Marra P, et al: Effective intraoperative hemostasis using a novel gelatin matrix: Report from 82 cancer surgery cases. Gastroenterology 2001;120(5)(1 Suppl):A481.
16. Tan L, Williams MA, Kan MK, et al: Risk of transmission of Bovine Spongiform Encephalopathy to humans in the United States. Report of the Council on Scientific Affairs. JAMA 1999;281:2330-2339.
17. Blackwelder WC, Chang MA: Sample size graphs for "proving the null hypothesis." Controlled Clin Trials 1984;5:97-105.
18. Goldstein DJ, DeRosa CM, Seldomridge JA, et al: Is aprotinin indicated for reoperative valvular surgery? J Heart Valve Dis 1997;6:88-92.
19. Goldstein DJ, DeRosa CM, Mongero LB, et al: Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 1995;110:1615-1621.
20. Goldstein DJ, Seldomridge JA, Chen JM, et al: Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 1995;59:1063-1068.
21. Forbes JM, Anderson MD, Anderson GF, et al: Blood transfusion cost: A multicenter study. Transfusion 1991;31:318-323.
22. Cryer HG, Mavroudis C, Yu J, et al: Shock, transfusion, and pneumonectomy: Death is due to right heart failure and increased pulmonary vascular resistance. Ann Surg 1990;212:197-201.
23. Tweddell JS, Berger S, Frommelt PC, et al: Aprotinin improves outcome of single-ventricle palliation. Ann Thorac Surg 1996;62:1329-1336.